News & Updates
Showing Multidisciplinary articles
Showing
Long-term lecanemab reduces cognitive decline in early AD
Treatment with lecanemab continue to provide benefits to patients with early Alzheimer’s disease (AD) through 24 months, according to the results of the ongoing open-label extension study of Clarity AD. Those who have been treated much later also show disease improvements.
Does BMI affect functional outcomes in stroke patients on rehab?
A study in Singapore provides further evidence regarding the benefits of poststroke rehabilitation in improving function, reducing disability, and discharging patients. In addition, the results show that body mass index (BMI) in any category does not predict the ability to attain functional independence following inpatient rehabilitation.
ALK+ NSCLC: Real-world patterns and outcomes of treatment after 1L brigatinib
Following first-line (1L) brigatinib treatment, most patients with ALK-positive (ALK+) non-small-cell lung cancer (NSCLC) received an ALK tyrosine kinase inhibitor (TKI) as second-line (2L) therapy and experienced prolonged clinical benefit, a retrospective chart review of patients enrolled in the phase III ALTA-1L trial has shown.
Speeding COVID-19 symptom recovery may not fall within the realm of nirmatrelvir–ritonavir
Treating COVID-19 patients who had been vaccinated or did not have risk factors for severe disease with ritonavir-boosted nirmatrelvir (nirmatrelvir–ritonavir) did not expedite the time to symptom alleviation, reported investigators in the EPIC-SR trial.
Smartphone app helps control blood sugar in people at risk of T2D
Use of a smartphone application (app) and an intermittently scanned continuous glucose monitoring (isCGM) results in better glycaemic control, lower carbohydrate intake, and weight loss in people at increased risk of type 2 diabetes (T2D), reports a study.